GLP1R and congestive heart failure: The 2021 clinical practice guidelines by the European Society of Cardiology (ESC) for the diagnosis and treatment of acute and chronic heart failure recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or SGLT2i in diabetic patients with established atherosclerotic cardiovascular diseases (ASCVDs) and/or target organ damage (TOD) to decrease cardiovascular events (class 1).